Citigroup Inc. lessened its holdings in Heska Corp (NASDAQ:HSKA) by 88.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,400 shares of the medical research company’s stock after selling 17,891 shares during the period. Citigroup Inc.’s holdings in Heska were worth $190,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of Heska by 110.1% in the 4th quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock valued at $16,897,000 after purchasing an additional 110,391 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Heska by 13.3% in the 4th quarter. Rhumbline Advisers now owns 14,785 shares of the medical research company’s stock valued at $1,186,000 after purchasing an additional 1,731 shares in the last quarter. Ranger Investment Management L.P. increased its stake in shares of Heska by 436.0% in the 4th quarter. Ranger Investment Management L.P. now owns 166,583 shares of the medical research company’s stock valued at $13,362,000 after purchasing an additional 135,505 shares in the last quarter. Redmile Group LLC purchased a new position in shares of Heska in the 4th quarter valued at about $15,753,000. Finally, Fred Alger Management Inc. increased its stake in shares of Heska by 27.3% in the 4th quarter. Fred Alger Management Inc. now owns 139,120 shares of the medical research company’s stock valued at $11,159,000 after purchasing an additional 29,844 shares in the last quarter. Hedge funds and other institutional investors own 89.16% of the company’s stock.
Several brokerages recently weighed in on HSKA. ValuEngine lowered Heska from a “buy” rating to a “hold” rating in a research note on Thursday, June 21st. Canaccord Genuity reiterated a “buy” rating and set a $123.00 price objective (up from $115.00) on shares of Heska in a research note on Friday, June 15th. BidaskClub lowered Heska from a “strong-buy” rating to a “buy” rating in a research note on Friday. Zacks Investment Research upgraded Heska from a “sell” rating to a “hold” rating in a research note on Thursday, May 3rd. Finally, Benchmark boosted their price objective on Heska from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, May 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Heska currently has a consensus rating of “Buy” and a consensus target price of $115.25.
In other news, COO Jason A. Napolitano sold 5,502 shares of the business’s stock in a transaction that occurred on Thursday, May 31st. The stock was sold at an average price of $106.08, for a total transaction of $583,652.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie J. Trowbridge sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $101.01, for a total value of $505,050.00. Following the transaction, the director now owns 6,249 shares in the company, valued at $631,211.49. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,202 shares of company stock valued at $2,752,523. 14.70% of the stock is owned by company insiders.
NASDAQ:HSKA opened at $102.41 on Tuesday. Heska Corp has a 12 month low of $56.59 and a 12 month high of $115.00. The company has a market cap of $761.03 million, a price-to-earnings ratio of 49.47 and a beta of 0.80.
Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Friday, May 4th. The medical research company reported $0.28 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by ($0.12). Heska had a return on equity of 13.30% and a net margin of 5.57%. The firm had revenue of $32.77 million for the quarter, compared to analysts’ expectations of $31.65 million. equities analysts anticipate that Heska Corp will post 1.68 earnings per share for the current year.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.